Moderna, Inc. (ETR:0QF)
| Market Cap | 9.20B |
| Revenue (ttm) | 2.62B |
| Net Income (ttm) | -2.47B |
| Shares Out | n/a |
| EPS (ttm) | -6.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 505 |
| Average Volume | 39,360 |
| Open | 24.78 |
| Previous Close | 24.59 |
| Day's Range | 23.63 - 24.78 |
| 52-Week Range | 19.89 - 54.20 |
| Beta | 2.01 |
| RSI | 53.79 |
| Earnings Date | Nov 6, 2025 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges
Shares of a social media juggernaut slumped as investors balked at its rapidly accelerating spending on artificial intelligence, while reports of potential partnership or buyout talks helped a vaccine...
Moderna (MRNA) Outperforms Broader Market: What You Need to Know
Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.
Notable Friday Option Activity: MRNA, MDB, RKLB
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Moderna Inc (Symbol: MRNA), where a total of 91,472 contracts have traded so far, represent...
UBS Adjusts Moderna (MRNA) Price Target to $40, Maintains Buy Rating | MRNA Stock News
UBS Adjusts Moderna (MRNA) Price Target to $40, Maintains Buy Rating | MRNA Stock News
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers...
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers...
JP Morgan Lowers Price Target for MRNA to $25, Maintains Underweight Rating | MRNA Stock News
JP Morgan Lowers Price Target for MRNA to $25, Maintains Underweight Rating | MRNA Stock News
December 5th Options Now Available For Moderna (MRNA)
Investors in Moderna Inc (Symbol: MRNA) saw new options begin trading today, for the December 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRNA options c...
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection
Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven and financial guidance. ... Full story available on Benzinga.com
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection
Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company's investigational cytomegalovirus (CMV) vaccine. CMV is a herpe...
Moderna to Host Investor Event - Analyst Day
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.
Moderna (MRNA) Halts Clinical Development of CMV Vaccine After Trial Results
Moderna (MRNA) Halts Clinical Development of CMV Vaccine After Trial Results
Moderna (MRNA) Halts CMV Vaccine Program as Late-Stage Trial Falls Short
Moderna (MRNA) Halts CMV Vaccine Program as Late-Stage Trial Falls Short
Stocks making the biggest moves after hours: IBM, Tesla, Moderna and more
These are the stocks posting the largest moves in extended trading.
Moderna ends development of CMV vaccine after trial failure
Moderna said on Wednesday it will discontinue development of its experimental vaccine to prevent cytomegalovirus, a common cause of birth defects, after it failed to meet the main goal of a late-stage...
Moderna drops as late-stage cytomegalovirus vaccine trial fails
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
Company to discontinue development of mRNA-1647 in congenital CMVCompany will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patientsCompany does not anticipate any ...
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate an...
Moderna Drops Vaccine for Birth Defects After Trial Failure
Should You Buy Moderna Right Now?
Shares could keep sliding, as Moderna's post-COVID pipeline has yet to reach a breakthrough.
mRNA COVID shots may bolster effects of cancer treatments: study
mRNA-based COVID shots such as those from Pfizer (PFE)/ BioNTech (BNTX) and Moderna (MRNA) could lift survival of cancer patients on immunotherapies. Read more here.
Dow Jumps More Than 500 Points Ahead Of Earnings: Investor Fear Eases, Greed Index Remains In 'Fear' Zone
The CNN Money Fear and Greed index showed further easing in the overall fear level, while the index remained in the “Fear” zone on Monday. U.S. stocks settled higher on Monday, with the Dow Jones inde...
Monday Sector Leaders: Healthcare, Technology & Communications
Looking at the sectors faring best as of midday Monday, shares of Healthcare companies are outperforming other sectors, higher by 1.5%. Within that group, Moderna Inc (Symbol: MRNA) and Cooper Compani...
Needham Reiterates Hold Rating for Moderna (MRNA) on October 20, 2025 | MRNA Stock News
Needham Reiterates Hold Rating for Moderna (MRNA) on October 20, 2025 | MRNA Stock News
Stock Market Today: S&P 500, Nasdaq, Dow Jones Futures Rise— Micron, Bitmine, Coinbase In Focus
U.S. stock futures rose on Monday following Friday’s advances. Futures of major benchmark indices were higher. On Sunday, President Donald Trump again warned that the U.S. economy would face significa...